Positions

Principal Investigator On

  • Identifying Predictors of Poor Health Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors  awarded by National Marrow Donor Program 2019 - 2023
  • PBMTC Study No. 1701 "Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children with B-ALL (Endrad) Trial"  awarded by CHILDREN'S HOSPITAL LA 2019 - 2022
  • Predictive Biomarkers of Pediatric Graft-Versus-Host Disease  awarded by Canadian Institutes of Health Research 2014 - 2019
  • A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients  awarded by New York Blood Center 2013 - 2018
  • 11-TREO: A Phase II Study of Treosulfane/Fiudarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children with AMLIMDS Undergoing Allogeneic Hematopoietic Cell Transplantation  awarded by National Marrow Donor Program 2013 - 2017
  • Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2015
  • Role of Allogenic Th1 Like Cells in Graft Versus Host Disease and Graft Versus Lukemia  awarded by HYUNDAI HOPE ON WHEELS 2012 - 2015
  • A Multi-Center, Randomized, Double-Blind, Phase III Trial Evaluating Corticosteroids with Mycophenolate Mofetil vs. Corticosteroids with Placebo as Initial Systemic Treatment of Acute GVHD  awarded by NATIONAL CHILDHOOD CANCER FOUNDATION 2010 - 2011
  • Investigator On

  • Private Grant  awarded by JAZZ PHARMACEUTICALS, INC. 2018 - 2028
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program 2017 - 2023
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2020
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2015 - 2020
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2017 - 2020
  • Screen to Intervene: Improving Family-Centered Psychosocial Screening  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2019 - 2020
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2020
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2020
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2018 - 2019
  • Primary Immune Deficiency Treatment Consortium  awarded by University of California, San Francisco 2016 - 2019
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • Private Grant  awarded by JAZZ PHARMACEUTICALS, INC. 2017 - 2019
  • A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders/ PBMTC PIDTC #6901  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2019
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP 2015 - 2018
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2018
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2017
  • Reduced-Intensity Conditioning for Children and Adults with Hemaphagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015
  • Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen / BMT CTN Protocol 0601  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2015
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2015
  • Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease  awarded by Emory University 2014 - 2015
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015
  • Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen / BMT CTN Protocol 601  awarded by NATIONAL CHILDHOOD CANCER FOUNDATION 2011 - 2014
  • The Role of Minimal Residual Disease Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia.  awarded by National Marrow Donor Program 2012 - 2014
  • Education And Training

  • Memorial Sloan Kettering Cancer Center, Postdoctoral Fellowship
  • University of Tennessee College of Medicine, Residency 2001
  • Memorial Sloan Kettering Cancer Center, Postdoctoral Fellowship 2004
  • Full Name

  • Joseph Chewning